Leadership

Mr. Mott is currently Chief Executive Officer and Chief Investment Officer of Sphinx Mountain Capital LLC, a family office investment business, and from February 2020 through August 2025 was a private investor through Mott Family Capital. He also serves as chairman of the board for Ardelyx, Inc (NASDAQ: ARDX), and is a member of the board for several non-profits. From 2008 to 2020, Mr. Mott was general partner at New Enterprise Associates (NEA), one of the world's largest venture capital firms, which invests in companies across all stages in healthcare and technology. At NEA, Mr. Mott led the healthcare investing practice with a personal focus within biotechnology.  Mr. Mott served as president and chief executive officer and vice chairman of MedImmune from 2000 through 2008, during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion. He joined MedImmune in 1992 and prior to becoming CEO in 2000 served in various senior roles, including chief operating officer, chief financial officer, and head of business development and strategy. 

During the course of his career, Mr. Mott has been involved in more than $40 billion in corporate acquisitions, fundraising, partnerships, and other capital formation. He has been involved in more than 35 initial public offerings, brought more than a dozen new drugs through development and commercialization, and served on 25 corporate boards. Mr. Mott holds a Bachelor of Arts degree from Dartmouth College.